In a quarter that was marked by the rapid spread of the COVID-19 pandemic, drug approvals continued (Table 1), but launching was a completely different matter. Zeposia (ozanimod), the most eagerly awaited new drug of the quarter, is not going to reach patients with multiple sclerosis soon, after Bristol- Myers Squibb announced that it would be delaying its debut.

Para acessar a publicação na íntegra clique aqui
Fonte: Nature Reviews | Drug DIScovery  NEWS & ANALYSIS volume 19 | May 2020 | 299